skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Issue

  • A product was about to go generic within the metastatic renal cell carcinoma (mRCC) indication. Our client wished to understand the potential impact of the competitor’s drug going generic on their brand and whether there would be any spill-over effects

 Approach

  • Pharma Intelligence Consulting selected a set of historical analog drugs to model past benchmarking.
  •  We adopted five analytical methods to selecting the right analogs:
    1) Bivariate analysis 2) Time series progression 3) Unit price differential 4) Market share evolution and 5) Weighted mean prioritization

Outcomes

  • Our comprehensive market report identified the most appropriate analogs for this therapeutic area and helped the client quantify the relationship between price-volume, and better understand the impact that pricing strategies can have on demand post LOE. Our analysis further outlined the speed and extent to which generic penetration occurs and the spill- over effects on share across the category. 
  • Our market segmentation based on the risk of generic exposure enabled the client to effectively strategize across regions.

Next steps

For a personal discussion, contact Christian Neckermann: 

+1 781-369-1527


Or email us your inquiry, so we can provide you the best possible customer service:
Christian.Neckermann@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: